Latest Strategy News

Mount Hope Mining Limited has confirmed robust copper, lead, silver, and zinc mineralisation at its Mount Hope Project through a recent soil survey, reinforcing the project's exploration potential ahead of planned drilling.

Ansell Limited has announced a USD 0.222 per share dividend for the six months ending December 2024, payable in March 2025 with a full dividend reinvestment plan available.

Ansell Limited has delivered a robust first half for FY25, reporting a near 30% increase in revenue and a remarkable 183.5% jump in net profit, driven by strong segment growth and strategic acquisition integration.

Xstate Resources has divested its 25% stake in the Crest Jinn assets in Alberta, Canada, opting for a modest royalty interest as it refocuses amid geopolitical and operational uncertainties.

PM Capital Global Opportunities Fund has declared a 5.5 cent fully franked interim dividend for H1 FY25 and reaffirmed its commitment to an 11.0 cent annual dividend, supported by a 6.0% portfolio return for the year ending December 2024.

PM Capital Global Opportunities Fund Limited reported an 11% rise in half-year profit to $39.8 million and declared a higher fully franked interim dividend of 5.5 cents per share, reflecting strong portfolio performance amid global market volatility.

Helios Energy Ltd has secured A$691,325 through interest-free Convertible Notes to advance its Presidio Project in Texas, ensuring regulatory compliance and operational continuity.

Citigroup Global Markets Australia has announced a fully franked dividend of AUD 1.10 for the REA Instalment MINI, with key dates set for early March 2025. This move aligns closely with the dividend schedule of the underlying REA Ordinary Security.

DMC Mining Limited has extended the closing date for its public share offer to May 8, 2025, due to delays in obtaining exploration licenses for its Firawa and Labe Projects in Guinea. The company plans to lodge a second supplementary prospectus to adjust regulatory conditions accordingly.

The Australian Office of Financial Management has issued a new 4.25% Treasury Bond due in 2036, set to begin trading on the ASX from February 13, 2025. This issuance adds a fresh long-term government debt instrument to the market.

Neuren Pharmaceuticals has received a significant cash inflow of approximately US$50 million following the sale of a Priority Review Voucher linked to its Rett syndrome treatment. This milestone underscores the growing value of Neuren’s neurological drug portfolio and its partnership with Acadia Pharmaceuticals.

Nyrada has secured ethics approval to begin its first-in-human Phase Ia trial of NYR-BI03, a promising neuro- and cardioprotective drug candidate. Recruitment starts soon, with dosing expected by March and results due in Q3 2025.